We are live on ! Find out more
APM

Avidity Partners Management Portfolio holdings

AUM $936M
1-Year Est. Return 195%
This Fund
S&P 500
This Quarter Est. Return
+7.14%
1 Year Est. Return
+195%
3 Year Est. Return
+460.87%
5 Year Est. Return
+815.5%
10 Year Est. Return
–
AUM
$4.51B
AUM Growth
+$814M
Cap. Flow
+$783M
Cap. Flow %
17.35%
Top 10 Hldgs %
40.45%
Holding
134
New
22
Increased
42
Reduced
20
Closed
29

Top Buys

Rank Stock Value
1
REGN icon
Regeneron Pharmaceuticals
REGN
+$94.6M
2
AZN icon
AstraZeneca
AZN
+$82.2M
3
BAX icon
Baxter International
BAX
+$68.1M
4
CRBU icon
Caribou Biosciences
CRBU
+$60.5M
5
STVN icon
Stevanato
STVN
+$59.9M

Top Sells

Rank Stock Value
1
MRVI icon
Maravai LifeSciences
MRVI
+$124M
2
MDT icon
Medtronic
MDT
+$66.4M
3
BIIB icon
Biogen
BIIB
+$63.7M
4
NEO icon
NeoGenomics
NEO
+$61.7M
5
LLY icon
Eli Lilly
LLY
+$58.1M

Sector Composition

Rank Sector Weight
1 Healthcare 84.59%
2 Technology 0.99%
3 Financials 0.53%
4 Consumer Discretionary 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
STVN icon
26
Stevanato
STVN
$5.41B
$64.3M 1.43%
+2,541,893
New +$59.9M
SHC icon
27
Sotera Health
SHC
$4.92B
$62.2M 1.38%
2,378,000
+468,000
+25% +$11.3M
IDYA icon
28
IDEAYA Biosciences
IDYA
$3.54B
$62.1M 1.38%
2,437,000
+367,000
+18% +$8.57M
CRBU icon
29
Caribou Biosciences
CRBU
$158M
$59.1M 1.31%
+2,474,067
New +$60.5M
CTLT
30
DELISTED
CATALENT, INC.
CTLT
$53M 1.17%
398,000
-142,000
-26% -$17.7M
GRTS
31
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
$48.1M 1.07%
4,457,831
+2,335,767
+110% +$21.3M
LEGN icon
32
Legend Biotech
LEGN
$3.73B
$45.2M 1%
894,000
+269,000
+43% +$11.2M
OCDX
33
DELISTED
Ortho Clinical Diagnostics Holdings plc Ordinary Shares
OCDX
$44.3M 0.98%
+2,398,000
New +$48.3M
PFE icon
34
Pfizer
PFE
$141B
$44.2M 0.98%
+1,026,800
New +$45.5M
ARWR icon
35
Arrowhead Research
ARWR
$12B
$42.1M 0.93%
673,700
+569,700
+548% +$36.9M
STTK icon
36
Shattuck Labs
STTK
$672M
$41.3M 0.91%
2,025,000
+84,800
+4% +$1.81M
RARE icon
37
Ultragenyx Pharmaceutical
RARE
$2.65B
$41M 0.91%
+455,000
New +$41.1M
IMCR icon
38
Immunocore
IMCR
$1.72B
$40.6M 0.9%
1,095,600
+494,600
+82% +$16.7M
RNAM
39
DELISTED
Avidity Biosciences
RNAM
$40.5M 0.9%
+1,645,000
New +$35.8M
IOVA icon
40
Iovance Biotherapeutics
IOVA
$2.19B
$36.1M 0.8%
+1,462,200
New +$34.5M
INSM icon
41
Insmed
INSM
$22.7B
$35.6M 0.79%
1,292,000
+141,950
+12% +$3.72M
EXAS
42
DELISTED
Exact Sciences
EXAS
$35.2M 0.78%
369,000
-221,000
-37% -$23.3M
CMPS
43
Compass Pathways
CMPS
$1.52B
$34.7M 0.77%
1,162,000
+162,000
+16% +$5.44M
ATEC icon
44
Alphatec Holdings
ATEC
$1.33B
$34M 0.75%
2,786,000
+165,000
+6% +$2.3M
NTLA icon
45
Intellia Therapeutics
NTLA
$1.49B
$33.7M 0.75%
251,000
-129,000
-34% -$19.5M
NBP
46
NovaBridge Biosciences American Depositary Shares
NBP
$206M
$32.9M 0.73%
454,000
-275,000
-38% -$19.9M
SPNE
47
DELISTED
SeaSpine Holdings Corporation Common Stock
SPNE
$30.6M 0.68%
1,943,000
+418,002
+27% +$7.15M
BLU
48
DELISTED
BELLUS Health Inc.
BLU
$30.3M 0.67%
4,942,000
+692,000
+16% +$2.62M
KYMR icon
49
Kymera Therapeutics
KYMR
$9.05B
$30.2M 0.67%
+514,500
New +$29.8M
CYT
50
DELISTED
Cyteir Therapeutics, Inc. Common Stock
CYT
$29.5M 0.65%
1,683,441
-124,953
-7% -$2.34M
1
2
3 4 5

Similar funds

NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
PWAM
Private Wealth Asset Management Cedar Rapids, Iowa $935M AUM 17.66% 1-Year Est. Return
LJAC
L.J. Altfest & Co New York $935M AUM 27.19% 1-Year Est. Return
NI
NetEase Inc Hangzhou, China $934M AUM 11.31% 1-Year Est. Return
MCM
Massar Capital Management Stamford, Connecticut $934M AUM 14.18% 1-Year Est. Return
TS
Tamar Securities Woodland Hills, California $934M AUM 26.74% 1-Year Est. Return
TW
TritonPoint Wealth Chevy Chase, Maryland $934M AUM 23.95% 1-Year Est. Return
PGA
Portland Global Advisors Portland, Maine $938M AUM 13.22% 1-Year Est. Return

Avidity Partners Management's Q3 2021 Portfolio in Review

As of Q3 2021, Avidity Partners Management held 134 positions worth $4.51B, up 22% from $3.7B the previous quarter. Its ten largest holdings account for 40% of the portfolio.

Avidity Partners Management deployed $783M of net new capital in Q3 2021, opening 22 new positions and adding to 42 existing holdings. Its largest new stake was Regeneron Pharmaceuticals: 152,300 shares worth $92.2M.

By sector, the portfolio is most concentrated in Healthcare at 85% of assets, down from 95% a quarter earlier, followed by Technology and Financials.

On the sell side, the largest reduction was Eli Lilly, an estimated $58.1M trimmed.

  • Avidity Partners Management's largest Q3 2021 buy was Regeneron Pharmaceuticals: 152,300 shares worth $92.2M.
  • Avidity Partners Management added most to Mirati Therapeutics, Inc. Common Stock in Q3 2021, an estimated $49.8M increase.
  • Avidity Partners Management's biggest Q3 2021 reduction was Eli Lilly, cutting an estimated $58.1M.
  • Avidity Partners Management fully exited Maravai LifeSciences in Q3 2021, selling an estimated $124M.
  • Avidity Partners Management's ten largest holdings make up 40% of its $4.51B portfolio in Q3 2021.
  • Avidity Partners Management opened 22 new positions and closed 29 in Q3 2021.
  • Avidity Partners Management's portfolio value rose 22% quarter-over-quarter to $4.51B.

Based on Avidity Partners Management's 13F filing for Q3 2021, filed 15 Nov 2021.